

References

1. European Science Foundation, European Medical Research Councils (EMRC), Forward Look Report, Consensus Conference, Le Bischenberg, France (2005).
2. http://www.nobelprize.org/nobel_prizes/medicine/laureates/1967/
3. http://www.nobelprize.org/alfred_nobel/
4. http://www.nobelprize.org/nobel_prizes/about/
5. Nobel Prize in Physics 1932: http://www.nobelprize.org/nobel_prizes/physics/laureates/1932/heisenberg-lecture.html
6. Arnold Sommerfeld was nominated a record 81 times but never received the Nobel Prize in physics. He was admired as a masterful teacher and mentor of a generation of great physicists, among them Nobel Laureates Werner Heisenberg, Wolfgang Pauli, Peter Debye, and Hans Bethe.
7. Nobel Prize in Medicine 1932: http://www.nobelprize.org/nobel_prizes/medicine/laureates/1931/index.html
8. Nobel Prize in Chemistry 1937: http://www.nobelprize.org/nobel_prizes/chemistry/laureates/1937/index.html
9. Nobel Prize in Medicine 1922: http://www.nobelprize.org/nobel_prizes/medicine/laureates/1922/index.html
10. Nadia Rosenthal, as quoted in her Foreword to "The Molecules of Life" by Russ Hodge, Facs On File, Infobase, NY (2009).
11. <http://en.wikipedia.org/wiki/Rhodopsin>
12. Nobel Prize in Chemistry 2012: http://www.nobelprize.org/nobel_prizes/chemistry/laureates/2012/press.html
13. http://www.nobelprize.org/nobel_prizes/medicine/laureates/1967/press.html
14. Bruce McManus, private communication. Adapted from Sykes RB, *New Medicines: The Practice of Medicine and Public Policy*, 2000, London, Nuffield Trust Publications Committee.

15. <http://copyright.gov/help/faq/faq-duration.html#duration>
16. <http://www.uspto.gov/faq/trademarks.jsp>
17. www.evpa.eu.com
18. William Swope, IBM Almaden Research, Private Communication.
19. <https://www.michaeljfox.org/foundation/news-detail.php?staff-on-the-move-foundation-unique-role-in-venture-philanthropy>
20. The electron volt (symbol eV) is a unit of energy, defined as the amount of energy associated with the movement of a single electron across an electric potential difference of one volt.
21. <http://www.unh.edu/news/docs/2007AngelMarketAnalysis.pdf>
22. This is not the place to discuss “high-energy physics.”
23. http://www.nobelprize.org/nobel_prizes/physics/laureates/1933/schrodinger-bio.html
24. The Hamiltonian or “Hamiltonian Operator” is related to the total energy of the system described by the Schrödinger equation. See [https://en.wikipedia.org/wiki/Hamiltonian_\(quantum_mechanics\)](https://en.wikipedia.org/wiki/Hamiltonian_(quantum_mechanics))
25. As of 2013, the official number is 98. However, lifetimes of some elements are so short that it’s more an academic debate whether to count more than 90 elements as “natural.” For more details see http://en.wikipedia.org/wiki/Periodic_table
26. “The Elements”, Jack Challoner, Carlton Books Ltd (2012), ISBN 978 1 78097 125 4.
27. Electronegativity is a useful concept first introduced by Linus Pauling to describe the tendency of an atom or a functional group to attract electrons towards itself. An atom’s electronegativity is affected by both its atomic number and the distance between its outer (“valence”) electrons and the charged nucleus. The most electronegative elements are the halogens (F, Cl, ...) and least electronegative are the alkali metals (Na, K, ...). See <https://en.wikipedia.org/wiki/Electronegativity>.
28. The only way to make all four bonds equivalent is to create a spatial sp³ hybridization with tetrahedral bond angles of 109°28’.
29. Semiconductor devices used to amplify and switch electronic signals and electrical power.
30. “Lithium in the prevention of suicidal behavior and all-cause mortality in patients with mood disorders: a systematic review of randomized trials” by Cipriani A., Pretty, H., Hawton, K., and Geddes, J.R. (2005). *Am J Psychiat*, **162**(10), pp. 1805–1819.
31. Eukaryotes are organisms whose cells contain a nucleus and other organelles enclosed within membranes. Most eukaryotic cells also

contain other membrane-bound organelles such as mitochondria. All multicellular organisms are eukaryotes, including animals, plants and fungi.

32. To be discussed in detail in a subsequent chapter.
33. Body fat or just fat (loose connective tissue).
34. <http://en.wikipedia.org/wiki/Glutamine>
35. <http://en.wikipedia.org/wiki/Arginine>
36. http://en.wikipedia.org/wiki/Jons_Jacob_Berzelius
37. http://www.nobelprize.org/nobel_prizes/chemistry/laureates/1958/
38. http://www.nobelprize.org/nobel_prizes/chemistry/laureates/1954/
39. http://www.nobelprize.org/nobel_prizes/physics/laureates/1914/
40. http://www.nobelprize.org/nobel_prizes/physics/laureates/1915/wh-bragg-facts.html
41. http://www.nobelprize.org/nobel_prizes/chemistry/laureates/2009/
42. http://en.wikipedia.org/wiki/Protein_Crystallization
43. Worldwide Protein Data Bank: <http://www ww p d b . o r g />
44. http://www.nobelprize.org/nobel_prizes/chemistry/laureates/1962/
45. http://www.nobelprize.org/nobel_prizes/chemistry/laureates/1972/anfinsen-bio.html
46. http://www.nobelprize.org/nobel_prizes/physics/laureates/1944/rabi-facts.html
47. http://www.nobelprize.org/nobel_prizes/physics/laureates/1952/
48. <http://scitation.aip.org/content/aip/magazine/physicstoday/article/56/3/10.1063/1.1570771>
49. HarperCollins Publishers (2006).
50. Recipient of the Nobel Prize in Physiology or Medicine 2002.
51. Nobel Prize in Physiology or Medicine 1968, http://www.nobelprize.org/nobel_prizes/medicine/laureates/1968/
52. See Nobel lecture 1968: http://www.nobelprize.org/nobel_prizes/medicine/laureates/1968/nirenberg-lecture.pdf
53. From p. 143 in Matt Ridley's book (reference number i above).
54. In 1980, Fredrick Sanger shared one half of the Nobel Prize in chemistry with Walter Gilbert for "determination of the sequence

- of the nucleotide blocks in DNA.” http://www.nobelprize.org/nobel_prizes/chemistry/laureates/1980/presentation-speech.html#
55. <http://www.biology.iupui.edu/biocourses/N100/2k3ch13dogma.html> (Indiana University)
 56. http://www.nobelprize.org/nobel_prizes/medicine/laureates/1974/presentation-speech.html
 57. http://www.nobelprize.org/nobel_prizes/chemistry/laureates/2009/presentation-speech.html
 58. http://www.nobelprize.org/nobel_prizes/medicine/laureates/1974/duve-facts.html
 59. http://www.nobelprize.org/nobel_prizes/medicine/laureates/1906/golgi-facts.html
 60. https://de.wikipedia.org/wiki/Biochemical_Pathways
 61. http://www.roche.com/media/roche_stories/roche-stories-2013-07-22.htm
 62. http://www.nobelprize.org/nobel_prizes/medicine/laureates/2013/press.html
 63. “What is Life” by Erwin Schrödinger, Cambridge University Press (first published 1944).
 64. http://www.nobelprize.org/nobel_prizes/physics/laureates/1918/
 65. http://en.wikipedia.org/wiki/Valence_bond_theory
 66. http://en.wikipedia.org/wiki/Luria%E2%80%93Delbr%C3%BCck_experiment
 67. “Evaluating plague and smallpox as historical selective pressures for the *CCR5-Δ32* HIV-resistance allele” by Galvani AP and Slatkin M (2003). *Proc Natl Acad Sci USA*, **100**(25), pp. 15276–15279.
 68. “On the origin of species by means of natural selection, or the preservation of favoured races in the struggle for life” by Charles Darwin (1859). John Murray, London; modern reprint Charles Darwin, Julian Huxley (2003). *On The Origin of Species*. Signet Classics. ISBN 0-451-52906-5.
 69. “Identifying signatures of natural selection in Tibetan and Andean populations using dense genome scan data” by Bigham A, Bauchet M, Pinto D, Mao X, Akey JM, Mei R, Scherer SW, Julian CG, Wilson MJ, López Herráez D, Brutsaert T, Parra EJ, Moore LG, and Shriver MD (2010). *PLoS Genet*, **6**(9), e1001116.
 70. “Adaptation and mal-adaptation to ambient hypoxia; Andean, Ethiopian and Himalayan patterns” by Xing G, Qualls C, Huicho L,

- Rivera-Ch M, Stobdan T, Slessarev M, Prisman E, Ito S, Wu H, Norboo A, Dolma D, Kunzang M, Norboo T, Gamboa JL, Claydon VE, Fisher J, Zenebe G, Gebremedhin A, Hainsworth R, Verma A, and Appenzeller O (2008). *PLoS ONE*, **3**(6), e2342.
71. "Altitude adaptation in Tibetans caused by introgression of Denisovan-like DNA" by Huerta-Sánchez E, Jin X, Asan, Bianba Z, Peter BM, Vinckenbosch N, Liang Y, Yi X, He M, Somel M, Ni P, Wang B, Ou X, Huasang, Luosang J, Cuo ZX, Li K, Gao G, Yin Y, Wang W, Zhang X, Xu X, Yang H, Li Y, Wang J, Wang J, and Nielsen R (2014). *Nature*, **512**, pp. 194–197.
 72. http://www.nobelprize.org/nobel_prizes/chemistry/laureates/1993/mullis-lecture.html
 73. http://www.nobelprize.org/nobel_prizes/medicine/laureates/1959/
 74. http://www.nobelprize.org/nobel_prizes/medicine/laureates/1978/
 75. "The Gene Wars" by Robert Cook-Deegan (1994). W W Norton & Co., New York; London.
 76. <http://genomesymposium.ucsc.edu/bio-sinsheimer.html>
 77. https://en.wikipedia.org/wiki/Craig_Venter
 78. <http://www.genome.gov/11006943>
 79. Huanming Yang (BGI), private communication.
 80. "Economic impact of the Human Genome Project" by S Tripp and M Grueber, Battelle Memorial Institute, May 2011.
 81. "Adsorption analysis and chromatographic method. Application to the chemistry of chlorophyll" by Mikhail Tswett (1906). *Proc Ger Bot Soc*, **24**, pp. 384–393.
 82. Fiers had spent 1960–62 at the California Institute of Technology to study viral DNA, and at the University of Wisconsin in Madison to work in the laboratory of Gobind Khorana (Nobel laureate 1968 for his work on nucleic acid synthesis in the study of the genetic code).
 83. "DNA sequencing with chain-terminating inhibitors" by Sanger F, Nicklen S, and Coulson AR (1977). *Proc Natl Acad Sci USA*, **74**(12), pp. 5463–5467.
 84. "A new method for sequencing DNA" by Maxam AM and Gilbert W (1977). *Proc Natl Acad Sci USA*, **74**(2), pp. 560–564.
 85. http://www.nobelprize.org/nobel_prizes/chemistry/laureates/1980/press.html
 86. http://www.nobelprize.org/nobel_prizes/chemistry/laureates/1980/gilbert-lecture.pdf

87. http://www.nobelprize.org/nobel_prizes/medicine/laureates/1959/kornberg-lecture.pdf, page 12
88. Fredrick Sanger died on November 19, 2013, at age 95. He won two Nobel prizes in chemistry: 1958 for protein (insulin) sequencing, 1980 for DNA sequencing.
89. Example and subsequent explanation adapted from Robert M. Cook-Deegan, ref. #71 above.
90. See his Nobel lecture, http://www.nobelprize.org/nobel_prizes/chemistry/laureates/1980/sanger-lecture.pdf
91. "The synthesis of oligonucleotides containing an aliphatic amino group at the 5' terminus: synthesis of fluorescent DNA primers for use in DNA sequence analysis" by Smith LM, Fung S, Hunkapiller MW, Hunkapiller TJ, and Hood LE (1985). *Nucleic Acids Res*, **13**(7), pp. 2399–2412.
92. <http://www.pacificbiosciences.com/aboutus/executives/list.html>
93. <http://www.jcvi.org/cms/press/press-releases/full-text/article/j-craig-venter-science-foundation-announces-500000-technology-prize-for-advances-leading-to-the/>
94. http://genomics.xprize.org/sites/genomics.xprize.org/files/docs/Competition_Fact_Sheet.pdf
95. "Real-time DNA sequencing using detection of pyrophosphate release" by Ronaghi M, Karamohamed S, Pettersson B, Uhlén M, and Nyrén P (1996). *Anal Biochem*, **242**(1), pp. 84–89.
96. http://en.wikipedia.org/wiki/454_Life_Sciences
97. <http://www.celldex.com/about/locations.php>
98. <http://www.genomeweb.com/sequencing/roche-shutting-down-454-sequencing-business>
99. http://en.wikipedia.org/wiki/Illumina_%28company%29
100. "Accurate whole human genome sequencing using reversible terminator chemistry" by DR Bentley, et al. (2008). *Nature*, **456**(7218), pp. 53–59.
101. "Accurate multiplex polony sequencing of an evolved bacterial genome" by Shendure J, Porreca GJ, Reppas NB, Lin X, McCutcheon JP, Rosenbaum AM, Wang MD, Zhang K, Mitra RD, and Church GM (2005). *Science*, **309**(5741), pp. 1728–1732.
102. <http://www.appliedbiosystems.com/absite/us/en/home/applications-technologies/solid-next-generation-sequencing/next-generation-systems/solid-sequencing-chemistry.html>
103. <http://www.lifetechnologies.com/us/en/home/about-us/news-gallery/company-fact-sheet/company-history.html>

104. <http://www.completegenomics.com/about-us/>
105. Picture copied from Complete Genomics web site.
106. <http://www.businessweek.com/articles/2012-12-20/complete-genomics-chinese-bid-sparks-a-security-fight>
107. <http://www.genomics.cn/en/index>
108. <http://www.pacificbiosciences.com/aboutus/history/>
109. "The \$1,000 Genome: The Revolution in DNA Sequencing and the New Era of Personalized Medicine" by Kevin Davies (2010). ISBN-10: 1416569596.
110. <http://www.xconomy.com/national/2014/03/03/pacbio-the-post-hype-sleeper-of-genomics/>
111. <http://www.agbt.org/about.html>
112. <http://investor.pacificbiosciences.com/releasedetail.cfm?ReleaseID=793199>
113. <http://dnae.co.uk/company/about/>
114. "An integrated semiconductor device enabling non-optical genome sequencing" by JM Rothberg, et al. (2011). *Nature*, **475**, pp. 348–352.
115. <http://www.genomeweb.com/sequencing/life-technologies-acquire-ion-torrent-725m>
116. <http://www.genomeweb.com/arrays/bionanomatrix-introduces-single-molecule-analyzer-researchers-ashg>
117. Picture copied from Bionano web site.
118. Vinod Makhijani, private communication.
119. <https://www.nanoporetech.com/>
120. "Characterization of individual polynucleotide molecules using a membrane channel" by Kasianowicz JJ, Brandin E, Branton D, and Deamer DW (1996). *Proc Natl Acad Sci USA*, **93**, pp. 13770–13773.
121. "Designed protein pores as components for biosensors" by O Braha, et al. (1997). *Chem Biol*, **4**, pp. 497–505.
122. <https://www.nanoporetech.com/technology/analytes-and-applications-dna-rna-proteins/dna-strand-sequencing>
123. "Nanopore in metal-dielectric sandwich for DNA position control" by Polonsky S, Rossnagel S, and Stolovitzky G (2007). *Appl Phys Lett*, **91**, p. 153103.
124. http://www.roche.com/media/media_releases/med_dia_2010-07-01.htm
125. Picture made available by IBM Research.

126. http://www.roche.com/media/media_releases/med-cor-2013-04-23.htm
127. "Recognition tunneling" by S Lindsay, et al. (2010). *Nanotechnology*, **21**(26), p. 262001.
128. "Comparison of next-generation sequencing systems" by Liu L, Li Y, Li S, et al. (2012). *J Biomed Biotechn* (Hindawi Publishing Corporation) 1-11.
129. AGBT 2014 talk by David Jaffe, Broad Institute; <http://www.broadinstitute.org/genome.bio/bios/bio-jaffe.html>
130. "The real cost of sequencing: higher than you think" by Sboner A, Mu XJ, Greenbaum D, Auerbach RK, and Gerstein MB (2011). *Genome Biol*, **12**(8), p. 125.
131. <https://github.com/samtools/hts-specs>
132. http://www.ebi.ac.uk/ena/about/cram_usage
133. "The variant call format and VCFtools" by Danecek P, Auton A, Abecasis G, Albers CA, Banks E, DePristo MA, Handsaker RE, Lunter G, Marth GT, Sherry ST, McVean G, and Durbin R (2011). *Bioinformatics*, **27**(15), pp. 2156-2158.
134. <https://web.archive.org/web/20120529215509/http://ohsr.od.nih.gov/guidelines/belmont.html>
135. <http://nuffieldbioethics.org/report/animal-research-2/animals-research/>
136. <http://nuffieldbioethics.org/about/>
137. <http://www.un.org/en/documents/udhr/index.shtml>
138. <http://www.un.org/en/documents/udhr/index.shtml>
139. <http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2010:276:0033:0079:en:PDF>
140. In 2005, Verity was acquired by AUTONOMY. Autonomy was then acquired by Hewlett-Packard (under short term CEO Leo Apotheker) for \$10.2B in October 2011.
141. <https://www.systemsbiology.org/hood-group>
142. <http://www.nytimes.com/2012/03/08/technology/cost-of-gene-sequencing-falls-raising-hopes-for-medical-advances.html?pagewanted=all>
143. <http://www.businessweek.com/articles/2012-12-20/complete-genomics-chinese-bid-sparks-a-security-fight>
144. <http://www.newsrx.com/library/newsletters/Biotech-Business-Week/2139633.html>

145. http://www.genomics.cn/en/news/show_news?nid=99717
146. <http://www.embo.org/news/press-releases/press-releases-2006/leading-scientists-elected-to-embo-ranks>
147. <http://twas.org/recipients-twas-awards-and-prizes>
148. <http://www.leopoldina.org/en/members/list-of-members/>
149. http://www.nasonline.org/member-directory/?q=BGI&site=nas_members
150. "Partnership Perspective: Merging a US Company and a Chinese Company" by Clifford A. Reid (Complete Genomics)", presentation at ICG-9 Conference, Shenzhen (China), Sep 9-11, 2014.
151. <http://www.genome.gov/27544383>
152. <http://www.ncbi.nlm.nih.gov/genome/>
153. "An integrated map of genetic variation from 1,092 human genomes" by RA Gibbs, et al. (2012). *Nature*, **491**(7422), pp. 56-65.
154. Paracelsus, Selected Writings, ed. with an introduction by Jolande Jacobi, trans. Norbert Guterman, (New York: Pantheon, 1951), pp. 79-80.
155. <http://www.gao.gov/new.items/d0749.pdf>, page 27
156. IBM Institute for Business Value analysis, based on data compiled by "Pharmaceutical Executive" (May 2012, pp. 24-34) and PhRMA Industry Profile 2012. (PhRMA = Pharmaceutical Research and Manufacturers of America).
157. See David Filmore, Modern Drug Discovery (MDD) Vol. 7, Issue 11, pp. 24-28 (Nov 2004).
158. http://www.nobelprize.org/nobel_prizes/chemistry/laureates/2012/
159. "The druggable genome" by Hopkins AL and Groom CR (2002). *Nat Rev Drug Discov*, **1**(9), pp. 727-730.
160. From a presentation (Feb 2002) given at IBM Research by Bennett M. Shapiro, M.D., Executive VP, Merck & Co., Inc.
161. http://www.nobelprize.org/nobel_prizes/medicine/laureates/2007/
162. http://www.nobelprize.org/nobel_prizes/chemistry/laureates/1984/press.html
163. "The rule of five" by CA Lipinski, et al. (1997). *Adv Drug Deliv Rev*, **23**, 3-25.
164. <http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=3672>
165. <http://www.fda.gov/AboutFDA/WhatWeDo/History/default.htm>

166. <http://www.umc-products.com/DynPage.aspx?id=73590&mn1=1107&mn2=1132>
167. <http://www.fda.gov/AboutFDA/Transparency/Basics/ucm194516.htm>
168. http://www.nobelprize.org/nobel_prizes/medicine/laureates/1908/press.html
169. http://www.nobelprize.org/nobel_prizes/medicine/laureates/1984/
170. <http://en.wikipedia.org/wiki/Biomarker>
171. http://www.fda.gov/cder/genomics/PGX_biomarkers.pdf
172. <http://www.fda.gov/oc/initiatives/criticalpath/>
173. "The FDA critical path initiative and its influence on new drug development" by Woodcock J and Woosley R (2008). *Annu Rev Med*, **59**, pp. 1–12.
174. "Stratified medicine: strategic and economic implications of coming drugs and clinical biomarkers" by Mark. R. Trusheim, Ernst R. Berndt and Frank L. Douglas (2007). *Nature Reviews Drug Discovery* **6**, pp. 287–293.
175. <http://en.wikipedia.org/wiki/Omeprazole>
176. <http://en.wikipedia.org/wiki/Nexium>
177. <http://en.wikipedia.org/wiki/Prozac>
178. <http://en.wikipedia.org/wiki/Paxil>
179. <http://en.wikipedia.org/wiki/Zoloft>
180. <http://en.wikipedia.org/wiki/Trastuzumab>
181. <http://en.wikipedia.org/wiki/Imatinib>
182. <http://www.gene.com/media/product-information/herceptin-development-timeline>
183. "Discovery of the Philadelphia chromosome: a personal perspective" by PC Nowell (2007). *J Clin Invest*, **117**(8), pp. 2033–2035.
184. http://en.wikipedia.org/wiki/Tau_protein
185. http://csdd.tufts.edu/reports/impact_reports
186. *Biomarkers In Drug Development*, John Wiley & Sons, Hoboken, New Jersey (2010).
187. "Knocked out" existing gene by replacing it or disrupting it with an artificial piece of DNA. The loss of gene activity often causes changes in a mouse's phenotype, which includes appearance, behavior and other observable physical and biochemical characteristics. Knockout mice are important animal models for studying the role of genes which have been sequenced but whose functions have not been determined.

188. "The Acquisition of Aventis by Sanofi", Case Study 306-238-1, University of St. Gallen, Institute of Management (2006).
189. http://www.ifb.unisg.ch/~media/Internet/Content/Dateien/InstituteUndCenters/IfB/Lehre/Lehrbuecher%20und%20Fallstudien/Case%20Studies/Aventis_I.306-238-1S_Inspection%20Copy_C.en.ashx
190. <http://www.abbvie.com/>
191. "From vision to decision: pharma 2020"; www.pwc.com/pharma2020; lead authors Steve Arlington, Joe Palo, Nick Davis.
192. <http://businesstoday.intoday.in/story/sun-pharma-ranbaxy-deal-indian-pharma-industry-cipla-dr-reddys-under-watch/1/207241.html>
193. <http://seekingalpha.com/article/1280811-china-biotech-in-review-simcere-receives-503-million-privatization-offer>
194. Letter from the CEO, Daniel Armbrust, Sematech. http://www.sematech.org/corporate/ceo_letter.htm
195. <http://www.imi.europa.eu/>
196. <http://www.efpia.eu/>
197. <http://www.nih.gov/science/amp/index.htm>
198. http://www.nobelprize.org/nobel_prizes/physics/laureates/1986/presentation-speech.html
199. "Beiträge zur Theorie des Mikroskops und der mikroskopischen Wahrnehmung" by Ernst Abbe (1873). *Archiv für Mikroskopische Anatomie*, **9**(1), pp. 413–468.
200. "Theory of the scanning tunneling microscope" by Tersoff J and Hamann DR (1985). *Phys Rev B*, **31**(1985), pp. 805–813.
201. http://www.nobelprize.org/nobel_prizes/physics/laureates/1919/
202. "Weyl's theory applied to the Stark effect in the hydrogen atom" by Hehenberger M, McIntosh HV, and Brandas E (1974). *Phys Rev A*, **10**, pp. 1494–1506.
203. $1 \text{ \AA} = 10^{-10} \text{ m} = 0.1 \text{ nm}$. The unit is named after the Swedish physicist Anders Jonas Ångström, one of the founders of the science of spectroscopy and appointed keeper of the Uppsala Astronomical Observatory.
204. "Press Release: The 1986 Nobel Prize in Physics," http://www.nobelprize.org/nobel_prizes/physics/laureates/1986/press.html
205. Gordon E. Moore, *Electronics*, April 19, 1965, pp. 114–117.

206. "Design of ion-planted MOSFETs with very small physical dimensions" by R Dennard, et al. (1974). *IEEE J Solid State Circuit*, **SC-9**(5), pp. 256–268.
207. http://www.ieee.org/about/awards/bios/moh_recipients.html
208. http://www.nobelprize.org/nobel_prizes/chemistry/laureates/2013/press.html
209. "Text-based knowledge discovery: search and mining of life sciences documents" by Mack R and Hehenberger M (2002). *Drug Discov Today*, **7**(11), pp. S89–S98.
210. <http://www.bloomberg.com/news/2011-02-16/don-t-read-this-unless-you-want-to-know-if-ibm-won-jeopardy-.html>
211. "Final Jeopardy: Man vs. Machine and the Quest to Know Everything" by Stephen Baker. (2011) Boston: Houghton Mifflin Harcourt.
212. "Natural language question-answering systems: 1969" by RF Simmons (1970). *Commun ACM*, **13**(1), pp. 15–30.
213. *IBM Journal of Research & Development*, **56**(3–4), (2012).
214. <http://www.research.ibm.com/cognitive-computing/index.shtml#fbid=pBmABym5xsF>
215. "Implicit text linkages between Medline records: using Arrowsmith as an aid to scientific discovery" by Swanson DR and Smalheiser NR (1999). *Libr Trends*, **48**(1), pp. 48–59.
216. "Trouble at the Lab," Economist.com, October 19–25, 2013, pp. 26–30.
217. "Why most published research findings are false" by John P A Ioannidis (2005). *PLoS Med*, **2**(8), e124.
218. "Drug development: raise standards for preclinical cancer research" by Begley CG and Ellis LM (2012). *Nature*, **483**(7391), pp. 531–533.
219. "Believe it or not: how much can we rely on published data on potential drug targets?" by Prinz F, Schlange T, and Asadullah K (2011). *Nat Rev Drug Discov*, **10**(9), p. 712.
220. Stanford University has created METRICS, the MEta-Research Innovation Center at Stanford.
221. Dialogue for Reverse Engineering Assessments and Methods. <http://www.the-dream-project.org/>
222. "Wisdom of crowds for robust gene network inference" by G Stolovitzky, et al. (2012). *Nat Meth*, **9**(8), pp. 796–804.
223. <http://depts.washington.edu/bakerpg/drupal/>
224. <http://homes.cs.washington.edu/~zoran/>

225. "Biologists enlist online gamers" by Katherine Bourzac (2008). *MIT Technology Review*, Biochemistry News, May 8, 2008.
226. "Online video game plugs players into remote-controlled biochemistry lab" by J Bohannon (2014). *Science*, **343**(6170), p. 475.
227. "Recent lessons learned from prevention and recent-onset type 1 diabetes immunotherapy trials" by Staeva TP, Chatenoud L, Insel R, and Atkinson MA (2013). *Diabetes*, **62**(1), pp. 9–17.
228. <http://jdrfconsortium.jaeb.org/ViewPage.aspx?PageName=Home>
229. "A pancreas in a box" by D Clery (2014). *Science*, **343**(6167), pp. 133–135.
230. http://www.medtronicdiabetes.com/treatment-and-products?utm_source=google&utm_medium=cpc&utm_campaign=RHW-Branded&utm_term=medtronic&utm_content=Medtronic|mkwid|smd7pQxkf-dc|pcrid|39204180121&gclid=CK_VttC9q7wCFY1QOgodkHoATw
231. "Cascade- and Nonskid-chain-like syntheses of molecular cavity topologies" by Buhleirier E, Wehner W, and Vögtle F (1978). *Synthesis*, **1978**(2), pp. 155–158.
232. "Click chemistry: diverse chemical function from a few good reactions" by Kolb HC, Finn MG, and Sharpless KB (2001). *Angew Chem Int Ed*, **40**(11), pp. 2004–2021.
233. "Self-assembly of a nanoscale DNA box with a controllable lid" by Andersen ES, Dong M, Nielsen MM, Jahn K, Subramani R, Mamdouh W, Golas MM, Sander B, Stark H, Oliveira CL, Pedersen JS, Birkedal V, Besenbacher F, Gothelf KV, and Kjems J (2009). *Nature*, **459**(7243), pp. 73–76.
234. "Nanonization strategies for poorly water-soluble drugs" by Chen H, Khemtong C, Yang X, Xhang X, and Gao J, (2011). *Drug Discov Today*, **16**(7–8), pp. 354–360.
235. <https://www.pharmadeals.net/journal/pharmadealsreview/fulltext/pdf/1471>
236. <http://www.alkermes.com/Research-and-Development/Technology-Platforms>
237. "Nanocrystal technology, drug delivery and clinical applications" by Junghanns JU and Müller RH (2008). *Int J Nanomed*, **3**(3), pp. 295–310.
238. "Mucoadhesive thiochitosan coated liposomes for oral administration of drugs" by Ruth Prassl, presented at CLINAM 7/2014.

239. "Nanotherapeutics in the EU: an overview on current state and future directions" by Hafner A, Lovrić J, Lakoš GP, and Pepić I (2014). *Int J Nanomed*, **9**, pp. 1005–1023.
240. "Basics of magnetic nanoparticles for their application in the field of magnetic fluid hyperthermia" by Mody VV, Singh A, and Wesley B (2013). *Eur J Nanomed*, **5**(1), pp. 11–21.
241. http://www.nobelprize.org/nobel_prizes/chemistry/laureates/1996/
242. "Buckysomes: new nanocarriers for anticancer drugs" by Danila D, Golunski E, Partha R, McManus M, Little T, and Conyers J (2013). *J Pharmaceutics*, **2013**(1–5), DOI: <http://dx.doi.org/10.1155/2013/390425>.
243. "Carbon nanotubes in biology and medicine: in vitro and in vivo detection, imaging and drug delivery" by Liu Z, Tabakman S, Welsher K, and Dai H (2009). *Nano Res*, **2**, pp. 85–120.
244. <http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm070570.pdf>
245. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2013/03/WC500140351.pdf
246. <http://www.clinam.org/>
247. "Analysis on the current status of targeted drug delivery to tumors" by Kwon IK, Lee SC, Han B, and Park K (2012). *J Control Release*, **164**, pp. 108–114.
248. "Drug targeting to tumors: principles, pitfalls, and (pre-)clinical progress" (2012) by Lammers T, Kiessling F, Hennink W, and Storm G (2012). *J Control Release*, **161**, pp. 174–187.
249. http://www.nobelprize.org/nobel_prizes/physics/laureates/1901/roentgen-facts.html
250. http://www.nobelprize.org/nobel_prizes/chemistry/laureates/1943/hevesy-facts.html
251. "Folded Stern-Gerlach experiment as a means for detecting nuclear magnetic resonance in individual nuclei" by JA Sidles (1992). *Phys Rev Lett*, **68**, 1124–1127.
252. "Force detection of nuclear magnetic resonance" by Rugar D, Zuger O, Hoen S, Yannoni CS, Vieth HM, and Kendrick RD (1994). *Science*, **264**, pp. 1560–1563.
253. <http://news.harvard.edu/gazette/story/2014/04/mri-on-a-molecular-scale/>
254. <http://www.marketwatch.com/story/bruker-announces-the-worlds-first-preclinical-magnetic-particle-imaging-mpi-system-2013-09-19>

255. <http://www.definiens.com/clinical/tissue-diagnostics.html>
256. http://www.zeiss.com/corporate/en_de/history/founders.html
257. http://www.nobelprize.org/nobel_prizes/chemistry/laureates/2014/
258. http://www.zeiss.com/microscopy/en_de/solutions/bioscience-tasks-applications/live-cell-imaging.html
259. <http://www.leica-microsystems.com/applications/life-science/fluorescence/>
260. <http://www.microscopyu.com/articles/fluorescence/>
261. <http://www.olympusmicro.com/primer/techniques/fluorescence/fluorhome.html>
262. <http://www.jeol.co.jp/en/corporate/outline/>
263. http://www.meijitechno.com/fluorescence_applications.htm
264. <http://www.roche.com/about/business/diagnostics.htm>
265. <http://www.qdvision.com/color-iq>
266. “Noninvasive imaging of quantum dots in mice” by Ballou B, Lagerholm BC, Ernst LA, Bruchez MP, and Waggoner AS (2004). *Bioconjug Chem*, **15**(1), pp. 79–86.
267. “An integrated semiconductor device enabling non-optical genome sequencing” by Jonathan M Rothberg, et al. (2011). *Nature*, **475**, pp. 348–352.
268. <http://nanophotonics.ece.cornell.edu/>
269. “Mid-IR Photonics” by William Green, Optical Fiber Communication Conference, San Francisco, California, March 9-13, 2014. <http://www.opticsinfobase.org/abstract.cfm?URI=OFC-2014-Th4I.4&origin=search>
270. “A case of cancer in which cells similar to those in the tumours were seen in the blood after death” by TR Ashworth (1869). *Aust Med J*, **14**, pp. 146–147.
271. “A new device for rapid isolation by size and characterization of rare circulating tumor cells” by I Desitter, et al. (2011). *Anticancer Res*, **31**(2), pp. 427–442.
272. <http://report.nih.gov/NIHfactsheets/ViewFactSheet.aspx?csid=62&key=R#R>
273. http://www.nobelprize.org/nobel_prizes/medicine/laureates/2012/
274. “Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors” by Takahashi K and Yamanaka S (2006). *Cell*, **126**(4), pp. 663–676.

275. http://en.wikipedia.org/wiki/Stem_cell
276. “Embryonic stem cell lines derived from human blastocysts” by Thomson JA, Itskovitz-Eldor J, Shapiro SS, Waknitz MA, Swiergiel JJ, Marshall VS, and Jones JM (1998). *Science*, **282**(5391), pp. 1145–1147.
277. http://www.nobelprize.org/nobel_prizes/medicine/laureates/2007/
278. <http://hsci.harvard.edu/aging-and-gdf11-what-we-know>
279. <http://www.upmc.com/Services/regenerative-medicine/research/cell-therapy/Pages/urinary-incontinence.aspx>
280. <http://www.wakehealth.edu/WFIRM/>
281. <http://www.the-scientist.com/?articles.view/articleNo/41052/title/The-Bionic-Eye/#eye2>
282. <http://bionicvision.org.au/eye;> <http://www.bionicsinstitute.org/Pages/default.aspx>
283. <http://www.retina-implant.de/default.aspx>
284. <http://www.pixium-vision.com/fr/>
285. http://www.rle.mit.edu/media/pr152/29_PR152.pdf
286. “Testing of semichronically implanted retinal prosthesis by supra-choroidal-transretinal stimulation in patients with retinitis pigmentosa” by T Fujikado, et al. (2011). *Invest Ophthalmol Vis Sci*, **52**, pp. 4726–4733.
287. “Gene Therapy for Human Genetic Disease?” by T. Friedmann and R. Roblin (1972). *Science* **175**(4025): 949–955.
288. “The discovery of zinc fingers and their applications in gene regulation and genome manipulation” by A Klug (2010). *Annu Rev Biochem*, **79**, pp. 213–231.
289. “Gene Therapy’s Second Act” by Ricki Lewis, *Scientific American* (March 2014), pp. 52–57.
290. <http://www.cira.kyoto-u.ac.jp/e/about/director.html>
291. <http://alliancerm.org/member-profiles>
292. <http://www.mesoblast.com/about-us/company-overview>
293. http://www.nobelprize.org/nobel_prizes/chemistry/laureates/1967/
294. http://www.medi-post.com/am_1.asp
295. <http://www.genengnews.com/gen-news-highlights/janssen-inks-up-to-337-5m-cell-therapy-collaboration-with-capricor/81249320/>
296. http://www.nobelprize.org/nobel_prizes/medicine/laureates/1958/lederberg-facts.html

297. <http://www.ucsf.edu/news/2014/08/116526/do-gut-bacteria-rule-our-minds>
298. <http://commonfund.nih.gov/hmp/index>
299. <http://www.human-microbiome.org/>
300. <http://www.earthmicrobiome.org/>
301. "Your microbes, your health" (December 2013). *Science*, **342**, pp. 1440–1441; www.sciencemag.org
302. <https://www.humanbrainproject.eu/discover/the-project/overview;jsessionid=1ssq42yfd44qq1qshcq6rwz4pr>
303. <http://www.braininitiative.nih.gov/index.htm>
304. <http://www.neuroscienceblueprint.nih.gov/connectome/>
305. "Speech production: Wernicke, Broca and beyond" by Blank SC, Scott SK, Murphy K, Warburton E, and Wise RJ (2002). *Brain*, **125**(Pt 8), pp. 1829–1838.
306. http://www.nobelprize.org/nobel_prizes/medicine/laureates/1997/
307. http://www.nobelprize.org/nobel_prizes/medicine/laureates/2014/
308. <http://www.wingsforlife.com/en/research>
309. <http://www.who.int/mediacentre/factsheets/fs297/en/>
310. http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx
311. <http://cancer.sanger.ac.uk/cancergenome/projects/cosmic/>
312. <http://cancergenome.nih.gov/>
313. <https://icgc.org/icgc>
314. "18FDG-PET predicts response to imatinib mesylate (Gleevec) in patients with advanced gastrointestinal stromal tumors" by AD Van den Abbeele, et al. (2002). *Proc Am Soc Clin Oncol*, **21**(1), 403a. The figure was presented by Richard A. Frank and GE Healthcare, at IBM's Imaging Biomarker Summit in Philadelphia, June 2006.
315. "Cancer immunotherapy" by Jennifer Couzin-Frankel (2013). *Science*, **342**, pp. 1432–1433. See also "Antibody therapeutics in cancer" by Sliwkowski MX and Mellmann I, (Genentech) (2013). *Science*, **341**, pp. 1192–1198.
316. "Human Ig superfamily CTLA-4 gene: chromosomal localization and identity of protein sequence between murine and human CTLA-4 cytoplasmic domains" by Dariavach P, Mattéi MG, Golstein P, and Lefranc MP (December 1988). *Eur J Immunol*, **18**(12), pp. 1901–1905.
317. "Enhancement of antitumor immunity by CTLA-4 blockade" by Leach DR, Krummel MF, and Allison JP (1996). *Science*, **271**, pp. 1734–1736.

318. <http://www.yervoy.com/patient.aspx>
319. <http://www.who.int/mediacentre/factsheets/fs317/en/>
320. "Cardiovascular therapy through nanotechnology: how far are we still from bedside?" by Cicha I, Garlich CD, and Alexiou C (2014). *Eur J Nanomed*, **6**(2), pp. 63–87.
321. "National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants" by Danaei G, Finucane MM, Lu Y, Singh GM, Cowan MJ, Paciorek CJ, et al. (2011). *Lancet*, **378**(9785), pp. 31–40.
322. <http://www.who.int/mediacentre/factsheets/fs312/en/>
323. <http://medicalxpress.com/news/2014-09-diabetes-faster-insulin-producing-cells.html>
324. "Generation of functional human pancreatic β cells in vitro" by Pagliuca FW, Millman JR, Gürtler M, Segel M, Van Dervort A, Ryu JH, Peterson QP, Greiner D, and Melton DA (2014). *Cell*, **159**(2), pp. 428–439.
325. "The intestinal microbiome in type 1 diabetes" by Dunne JL, Triplett EW, Gevers D, Xavier R, Insel R, Danska J, and Atkinson MA (2014). *Clin Exp Immunol*, **177**(1), pp. 30–37.
326. <http://www.smartglobalhealth.org/issues/entry/infectious-diseases>
327. <http://www.gatesfoundation.org/What-We-Do/Global-Development/Vaccine-Delivery>
328. <http://www.gavi.org/>
329. http://www.nobelprize.org/nobel_prizes/medicine/laureates/1945/fleming-facts.html
330. http://www.nobelprize.org/nobel_prizes/medicine/laureates/1939/domagk-facts.html
331. http://www.nobelprize.org/nobel_prizes/medicine/laureates/1945/florey-facts.html
332. http://www.nobelprize.org/nobel_prizes/medicine/laureates/1945/chain-facts.html
333. http://www.nobelprize.org/nobel_prizes/chemistry/laureates/1964/hodgkin-facts.html
334. "Extensively drug-resistant tuberculosis" by P LoBue (2009). *Curr Opin Infect Dis*, **22**(2), pp. 167–173.

335. "Biodegradable nanostructures with selective lysis of microbial membranes" by Nederberg F, Zhang Y, Tan JP, Xu K, Wang H, Yang C, Gao S, Guo XD, Fukushima K, Li L, Hedrick JL, and Yang YY (2011). *Nat Chem*, **3**(5), pp. 409–414.
336. http://www.nobelprize.org/nobel_prizes/medicine/laureates/1975/baltimore-facts.html
337. <http://www.who.int/mediacentre/factsheets/fs103/en/>
338. http://www.who.int/medicines/publications/essentialmedicines/18th_EML.pdf
339. "Free energy simulations reveal a double mutant avian H5N1 virus hemagglutinin with altered receptor binding specificity" by Das P, Li J, Royyuru AK, and Zhou R (2009). *J Comput Chem*, **30**(11), pp. 1654–1663.
340. "Mitigation strategies for pandemic influenza in the United States" by Germann TC, Kadau K, Longini IM Jr, and Macken CA (2006). *Proc Natl Acad Sci USA*, **103**(15), pp. 5935–5940.
341. "Kidneys on demand" by A Griffin (2007). *Brit Med J*, **334**(7592), pp. 502–505.
342. <http://www.nlm.nih.gov/medlineplus/druginfo/meds/a601117.html>
343. <http://health.usnews.com/best-hospitals/rankings>
344. <http://grad-schools.usnews.rankingsandreviews.com/best-graduate-schools/top-medical-schools/research-rankings>
345. www.sciencemag.org, Vol. 344, pp. 24–25, 4 April 2014
346. www.sciencemag.org/special/breastcancer, 28 March 2014
347. <http://www.cccb.org/2013/12/02/darpa-announces-two-programs-as-part-of-white-house-brain-initiative/>
348. <http://ec.europa.eu/programmes/horizon2020/en/area/health>
349. <http://www.mrc.ac.uk/About/Factsfigures/index.htm>
350. <http://www.mpg.de/institutes>
351. <http://www.uicc.org/membership/institut-gustave-rousseau>
352. <http://ki.se/en/about/ki-in-brief>
353. <http://www.ncc.go.jp/en/about/chronology.html>
354. <http://www.riken.jp/en/about/>
355. <http://www.research.a-star.edu.sg/>
356. <http://nrpgm.sinica.edu.tw/en/content.php?cat=agtc>
357. <http://www.csiro.au/Organisation-Structure/Divisions/Animal-Food-and-Health-Sciences.aspx>

358. <https://www.vlsci.org.au/>
359. <http://www.csir.res.in/home.asp>
360. <http://www.genomics.cn/en/index>
361. <http://www.fiercehealthpayer.com/story/kaisers-integrated-healthcare-model-could-benefit-other-insurers/2013-02-20>
362. <http://www.hl7.org/about/index.cfm?ref=nav>
363. <http://www.cdisc.org/mission-and-principles>
364. <http://www.fda.gov/>
365. http://www.ema.europa.eu/ema/index.jsp?curl=pages/home/Home_Page.jsp&mid=
366. http://www.nytimes.com/2014/03/16/science/billionaires-with-big-ideas-are-privatizing-american-science.html?_r=0
367. Jennifer Couzin-Frankel, "Chasing the Money", *Science* Vol. 344, pp. 25–26; 4 April 2014.
368. <http://www.hhmi.org/about/history>
369. <http://www.gatesfoundation.org/Who-We-Are>
370. <http://www.gatesfoundation.org/Who-We-Are/General-Information/Foundation-Factsheet>
371. http://en.wikipedia.org/wiki/The_Giving_Pledge
372. <http://www.wellcome.ac.uk/About-us/index.htm>
373. http://en.wikipedia.org/wiki/Frederick_Sanger
374. <http://www.jax.org/milestones/nobels.html>
375. <http://www.salk.edu/about/history.html>
376. http://www.nobelprize.org/nobel_prizes/medicine/laureates/1962/crick-facts.html
377. http://www.nobelprize.org/nobel_prizes/medicine/laureates/1969/luria-facts.html
378. http://www.nobelprize.org/nobel_prizes/medicine/laureates/1965/monod-facts.html
379. <http://wi.mit.edu/about>
380. <http://www.broadinstitute.org/>
381. <http://www.broadinstitute.org/history-leadership/board-directors/bios/eric-lander>
382. <http://wyss.harvard.edu/viewpage/71/leadership>
383. http://www.alleninstitute.org/about_us/background.html
384. <http://www.kavlifoundation.org/about-foundation>

385. <http://www.kavlifoundation.org/institutes>
386. <http://www.kavlifoundation.org/eric-r-kandel>
387. <http://mcgovern.mit.edu/about-the-institute/facts-at-a-glance>
388. http://www.idg.com/www/home.nsf/docs/remembering_pat_mcgovern
389. <http://www.stanleyresearch.org/dnn/Overview/tabid/36/Default.aspx>
390. <http://www.broadinstitute.org/psych/stanley>
391. <http://www.wingsforlife.com/en/about-us/#history>
392. http://en.wikipedia.org/wiki/Dietrich_Mateschitz
393. <http://www.efa-net.eu/member-news/news-from-austria/105-red-bull-founder-gives-biggest-donation-in-austrian-history>
394. <https://www.michaeljfox.org/foundation/michael-story.html>
395. <https://www.michaeljfox.org/foundation/publication-detail.html?id=341&category=7>
396. http://www.alz.org/about_us_about_us.asp
397. <http://banneralz.org/why-bai/about-bai.aspx>
398. <http://banneralz.org/news-plus-media/banner-alzheimer%27s-institute-news.aspx>
399. <http://ki.mit.edu/>
400. http://www.nobelprize.org/nobel_prizes/medicine/laureates/1969/
401. http://en.wikipedia.org/wiki/Jon_Huntsman,_Sr
402. <http://www.stjude.org/stjude/v/index.jsp?vgnextoid=58034c2a71fca210VgnVCM1000001e0215acRCRD>
403. <http://www.cancer.org/aboutus/whoweare/our-history>
404. <http://www.pcf.org/site/c.leJRIROrEPh/b.5699537/k.BEF4/Home.htm>
405. <http://www.curemelanoma.org/about-mra/mra-overview/>
406. <http://www.fastercures.org/about/what-we-do/>
407. http://www.ohsu.edu/xd/about/news_events/news/2013/09-21-nike-co-founder-issues-b.cfm
408. <http://www.ohsu.edu/xd/education/schools/school-of-medicine/about/druker091609.cfm>
409. <http://www.cancer.org/index>
410. <http://ww5.komen.org/AboutUs/FinancialInformation.html>
411. http://en.wikipedia.org/wiki/Woody_Johnson
412. http://www.diabetes.org/about-us/?loc=util-header_aboutus

413. <http://main.diabetes.org/dorg/PDFs/Financial/2012-american-diabetes-association-annual-report.pdf>
414. <http://www.cff.org/AboutCF/>
415. http://en.wikipedia.org/wiki/Francis_Collins
416. <http://www.whitehouse.gov/the-press-office/2013/04/02/fact-sheet-brain-initiative>
417. <http://www.whitehouse.gov/share/brain-initiative>
418. http://fmurray.scripts.mit.edu/docs/Murray_IPE2012_Science_Philanthropy_13102.proof.pdf
419. "An Economic Engine: NIH Research, Employment, and the Future of the Medical Innovation Sector" by Everett Ehrlich, United for Medical Research (Spring 2011). Updated 2012: http://www.unitedformedicalresearch.com/advocacy_reports/nihs-role-in-sustaining-the-u-s-economy/
420. http://www.who.int/nmh/global_monitoring_framework/en/
421. <http://www.reuters.com/article/2014/09/11/us-southkorea-smoking-idUSKBN0H60XT20140911>
422. "Health in all policies-the Finnish initiative: background, principles, and current issues" by Puska P and Ståhl T (2010). *Annu Rev Public Health*, **31**, pp. 315–328.
423. <http://www.healthdata.org/>
424. WHO Statistical data: <http://apps.who.int/ghodata/?theme=country>
425. "Pocket world in figures," *The Economist* (2013 Edition).
426. "Consumer-driven health care: lessons from Switzerland" by Herzlinger RE and Parsa-Parsi R (2004). *JAMA*, **292**(10), pp. 1213–1220.
427. www.ey.com/progressions, 2012, <http://www.ey.com/GL/en/Industries/Life-Sciences/Bringing-convenience-and-efficiency-to-health-care>
428. <http://www.cdc.gov/>
429. <http://aspe.hhs.gov/poverty/12poverty.shtml>
430. "Public Law 111–148." 111th United States Congress. Washington, D.C.: United States Government Printing Office. March 23, 2010.
431. <https://www.govtrack.us/congress/bills/111/hr3590/text>
432. "Obamacare: Experimental Medicine." *The Economist*, Sep 20–26, 2014, pp. 25–27.
433. "A Health Care Success Story" by Bob Kocher and Farzad Mostashari; NY Times OP-ED, 24 Sep 2014, p. A31.

Index

- \$1K genome *see* \$1,000 human genome
- \$1000 human genome 113
- 3D bioprinting 260, 271
- 3D visual system 292
- 23andMe 146
- 454 *see* 454 Life Sciences
- 454 Life Sciences 115
- 1000 Genomes Project 155

- A*STAR *see* Agency for Science, Technology and Research
- Astrom Biosciences 279
- abatacept *see* Orencia
- AbbVie 181
- ABI *see* Applied Biosystems
- Abraxane 230
- Academia Sinica 338
- academic medical research centers 335
- Accelerating Medicines Partnership 203
- accountable care organizations 367
- acetaminophen 170
- ACO *see* accountable care organizations
- ACT *see* Advanced Cell Technology
- Actavis 198
- acute lymphoblastic leukemia 266, 305
- acute myocardial infarction 270
- AD *see* Alzheimer's disease

- ADA *see* American Diabetes Association
- adenine 46
- adenosine-5'-triphosphate 26, 90, 162, 215
- ADME 171
- adult stem cells 255
- Advanced Cell Technology 273
- Advances in Genome Biology and Technology 122
- Advil *see* ibuprofen
- Affordable Care Act 366
- AGBT *see* Advances in Genome Biology and Technology
- Agency for Science, Technology and Research 338
- AGTC *see* Applied Genetic Technologies Corporation
- alanine 57
- Albert Sabin 330
- alcohol 40–41
- Aleve *see* Naproxen
- Alexion 198
- ALL *see* acute lymphoblastic leukemia
- Allen Institute for Brain Science 347, 354
- Alliance for Regenerative Medicine 268
- allografts 330
- alpha-helix 65–66
- ALSAC *see* St. Jude Children's Research Hospital
- Altor Bioscience Corporation 283

- Alzheimer's Association 203, 348
Alzheimer's disease 104, 188, 239, 291, 297–298, 348
American Cancer Society 351
American Diabetes Association 203, 352
Amgen 179, 198, 233, 280, 283
AMI *see* acute myocardial infarction
amino acids 55
AMP *see* Accelerating Medicines Partnership
AMRC *see* academic medical research centers
Andes 98–99
angel investors 14, 374
angiography 236
animal models 164–166, 197, 347
antagonistic antibodies 309
antibiotic resistance 318–320
antibiotics 188, 196, 286, 317–319, 321–322, 330
antidepressant 184
antimicrobial polymer nanoparticles 316, 321
antiretroviral drugs 328
APOE *see* apolipoprotein E
apolipoprotein E 299
Applied Biosystems 111
Applied Genetic Technologies Corporation 273
archaea 60, 103, 287
archenteron 253
arginine 58, 61
Argos Therapeutics 275
ARM *see* Alliance for Regenerative Medicine
Artificial Pancreas Project 214–217, 313, 332
asparagine 58, 60, 73
aspartic acid 57–59
aspirin 169–170, 175
Astra-Zeneca 194
Athersys 277–278
atoms 17
ATP *see* adenosine-5'-triphosphate
Au *see* gold
autografts 330
AUTONOMY 136
Avastin 181, 356
Avicenna 158
axons 263, 292, 294, 304

bacteria 103
Baltimore classification 323
BAM *see* binary sequence alignment/map
Banner Alzheimer's Institute *see* Alzheimer's Association
Battelle Memorial Institute 150
Bayer 194, 198, 233, 272, 318
BBB *see* blood-brain barrier
BCR-ABL 186
Beijing Genome Institute 339
Beike Biotechnology 267
belatacept 309
BENEFICENCE 137
benzene 23, 34–35
Berkshire Hathaway 342
Berzelius 63
beta sheet 65, 67
Betalogics 314
BGI 99, 121, 145–150, 250, 339
BGI *see* Beijing Genome Institute
big data 131, 197
Bill & Melinda Gates Foundation 342, 358
binary sequence alignment/map 133
bioavailability 171
biobanks 140
bioethics 135
Biogen 180, 198, 204, 355
bioinformatics 152, 167
biologics 176
biomarker 183
biomaterials 217

- biomedical imaging 234–235, 243
- biomedical research budget 336
- Bionano Genomics 123
- bionic 262–263, 332, 371
- bionic eye 262–263, 332, 371
- Bionic Vision Australia 263
- biosimilars 182
- BioTime 273
- blastocyst *see* blastula
- blastula 252–254
- blockbuster business model 193, 201
- blood–brain barrier 171, 298
- BMGF *see* Bill and Melinda Gates Foundation
- BMI *see* body mass index
- BMP-11 *see* bone morphogenetic protein 11
- BMS *see* Bristol-Myers Squibb
- body mass index 304, 362
- bone marrow transplantation 270
- bone morphogenetic protein 11 258
- BOWTIE 134
- Bragg 68–69
- brain 290
- brain *see* Broca's area
- brain *see* Wernicke's (speech) area
- BRAIN 291, 354
- BRCA1 141
- BRCA2 *see* BRCA1
- breast cancer research 336, 351
- Bristol-Myers Squibb 204, 230
- Broad Institute 345, 348
- Broca's area 295
- bubonic plague 98
- Buckyballs 232
- BVA *see* Bionic Vision Australia

- C *see* carbon
- Ca *see* calcium
- calcium 24, 29–30, 94, 163, 235, 275
- California Institute for Regenerative Medicine 273
- cancer 304
- cancer *see* metastases
- cancer genome 156, 305–307
- Cancer Genome Anatomy Project 156
- Cancer Genome Atlas 156, 306
- The Cancer Genome Atlas 306
- Cancer Genome Project 156, 306–307
- Capricor 278–279
- capsid 323
- carbohydrates 39
- carbon 25
- carbon nanotube 232
- carboxyl group 41–42, 63–64
- cardiovascular disease 310
- CCD *see* charged-coupled device
- CDC *see* Center for Disease Control
- CDI *see* Cellular Dynamics International
- CDISC 340
- Celebrix 171
- Celera 106, 141
- Celgene 198, 268, 270, 283
- celiac disease 286–287, 309
- cell 86
- cell cycle 55, 90, 306
- cell growth 55, 86, 90, 305
- Celladon 275
- cellular differentiation 55, 91, 153, 163
- Cellular Dynamics International 277
- Center for iPS Cell Research and Application 266
- Centers for Disease Control 341, 362
- central nervous system 94, 172, 215, 290–291, 293, 295, 297, 299, 301, 303
- cerebral cortex 292–295, 297
- CETUS 100–101

- CFF *see* Cystic Fibrosis Foundation
- CGM *see* continuous glucose monitoring
- chain termination 110–111
- charged-coupled device 115
- charitable foundations 342
- chemical synthesis 167, 177, 346
- cheminformatics 167
- chemotherapy 179, 181, 186, 227–228, 230, 282, 308
- CHF *see* congestive heart failure
- Chiesi Farmaceutici 229, 276
- chirality 56
- chlorine 23–24, 32, 330
- cholesterol 43–44, 163, 188, 195
- chromosome 81, 85, 89, 97, 186–187, 265
- chronic kidney disease 229
- cigarette smoking 363
- CiRA, Kyoto *see* Center for iPS Cell Research and Application
- circuit simulation 210
- circulating tumor cells 248
- CIRM *see* California Institute for Regenerative Medicine
- CKD *see* chronic kidney disease
- CLINAM 234
- clinical research organizations 339
- clinical trials 174
- cloning 103
- CMOS *see* complementary metal–oxide–semiconductor
- CNS *see* central nervous system
- CNT *see* carbon nanotube
- codons 57–62, 81–82
- cognitive computing 197, 212–213
- cognitive dysfunction 95, 142, 188, 239, 300, 371
- colloid chemistry 220
- combinatorial chemistry 167, 169–170, 192
- Commonwealth Scientific and Industrial Research Organisation 338
- complementary metal–oxide–semiconductor 245
- Complete Genomics 119
- computed tomography 74, 235, 240, 307
- conduction band 22, 36–37, 244
- cones 5, 262–263
- congenital disorder 251
- congestive heart failure 270
- conscience 292
- continuous glucose monitoring 216, 313
- copper 2, 24, 31–32, 235, 280
- cortex *see* left hemisphere
- cortex *see* right hemisphere
- COSMIC 306
- Council of Scientific and Industrial Research 339
- covalent 23
- coverage 131
- COX-1 169–170
- COX-2 *see* COX-1
- Craig Venter 106, 113
- CRAM 133
- critical path initiative 183, 191
- CRO *see* clinical research organizations
- cross-licensing 200
- crowdsourcing 213–214
- CSIR *see* Council of Scientific and Industrial Research
- CSIRO *see* Commonwealth Scientific and Industrial Research Organisation
- CT *see* computed tomography
- CTC *see* circulating tumor cells
- CTLA-4 *see* cytotoxic T-lymphocyte antigen 4
- Cu *see* copper
- CVD *see* cardiovascular disease
- Cyborg 371

- cysteine 57–58, 60, 66
 Cystic Fibrosis Foundation 352
 cytopathology 241
 cytoplasm 87–90, 93, 323, 328
 Cytori Therapeutics 279
 cytosine 47–49, 53, 78, 154
 cytotoxic T-lymphocyte antigen
 4 308
- DARPA *see* Defense Advanced
 Research Projects Agency
 Darwin 96, 98
 data analysis 130–131
 David Deamer 125
 DBS *see* deep brain stimulation
 DCE-MRI 238
 deep brain stimulation 300
 deer tick 315
 Defense Advanced Research
 Projects Agency 336
 Definiens 241
 dementia 298
 dendrimers 217
 dendritic encapsulation 218
 Dengue virus 322
 Denisovan 100
 deoxynucleotides 111
 deoxyribonucleotides 51
 deoxyribose 50–51
 Department of Defense 336
 Department of Energy 336
 depression 142, 286, 298–300,
 337
 diabetes 312
 diagnostic tests *in vitro* 243
 diagnostic tests *in vivo* 243
 dideoxynucleotides 111
 diploid 84–85, 95–96
 DKFZ *see* German Cancer Research
 Center
 DNA, RNA 46–47, 90, 136, 323
 DNA Electronics 123, 144
 DNA microarray 153, 246
 DNA polymerase 101
 DNA sequencing 106
 DNA transistor 128–129
 docking 93, 168
 DOD *see* Department of Defense
 DOE *see* Department of Energy
 Dolly 104–105
 dominant 83
 Dorothy Crowfoot Hodgkin
 318–319
 double helix 78, 82, 102, 109
 Doug Melton 314
 downstream analysis 116,
 131–132, 134
 Doxil 224, 226–229, 234
 Doxorubicin 227, 229
 DREAM project 214
 drug carriers 222
 drug delivery 93, 193, 197, 205,
 214, 217, 219, 221–227, 229,
 231–234, 281, 285, 311–312
 drug discovery 160
 drug target 160, 167
 druggable genes 164
- Earth Microbiome Project 289
 EBI *see* European Bioinformatics
 Institute
 Ebola virus 324–325
 Ebola virus disease 324
 The Economist 214, 359, 366–367
 ectoderm 253–255
 Edward Jenner, Jonas Salk 330
 EEG *see* electroencephalography
 EFPIA 202–203
 EKG *see* electrocardiography
 electrocardiography 241
 electroencephalography 235
 electron microscope 172, 206
 elements *see* atoms
 Eli Lilly 179
 Ellison Medical Foundation 346

- ELSI *see* ethical, legal, and social issues
- EMA *see* European Medicines Agency
- embryonic stem cells 104, 165, 252, 256
- EMP *see* Earth Microbiome Project
- EMT *see* epithelial-mesenchymal transition
- ENCODE Project 156
- endoderm 253–255, 281
- Endoplasmic reticulum 87
- endoscope 302
- Enterococcus faecalis 320
- enveloped viruses 324, 327
- enzymes 161
- EPAS1 gene 99–100
- epigenetics 49, 154
- epitaxy 245
- epithelial 254, 326
- epithelial–mesenchymal transition 254
- EPO *see* European Patent Organization
- Epogen 179
- Eric Lander 149, 345
- Ernst Ruska 206
- erythropoietin *see* Epogen
- Escherichia coli* 101, 178, 318
- esophagus 260
- esterases 161–162
- esters 42, 46, 162
- EteRNA project 214
- ethical, legal, and social issues 108, 148
- Ethiopia 98–99, 359
- EU *see* European Union
- eukaryote 90
- European Bioinformatics Institute 134
- European Medicines Agency 233, 340
- European Patent Organization 141
- European Union 337
- EVD *see* Ebola virus disease
- Evotec 272, 314
- exons 81–82
- Faster Cures 350
- FASTQ 133
- fatal familial insomnia 295
- fats 42, 46, 358
- fatty acid 42, 163
- FDA *see* Food & Drug Administration
- Fe *see* iron
- Fibrocell Science 276
- fludeoxyglucose 235
- fluorescence microscope 323
- fluoroscope 302
- fMRI *see* functional MRI
- Food and Drug Administration 160, 217, 340
- Francis Collins 106, 141, 149, 352
- Francis Crick 77, 79, 344
- Frank L. Douglas 184
- Frederick Sanger 65, 343
- functional MRI 237
- G-protein–coupled receptors 160, 161
- G *see* guanine
- gadolinium 238
- Galen of Pergamon 158
- gamete 85, 251
- Gamida Cell 280
- GAO *see* US Government Accountability Office
- gastrulation 253–255
- GAVI *see* Global Alliance for Vaccines and Immunization
- Gd *see* gadolinium
- GDF11 *see* growth differentiation factor 11
- GDP *see* gross domestic product
- GE *see* General Electric

- gene expression 91, 153–154, 156, 271, 276
- gene therapy 251
- Genentech 179, 181–182, 185–186, 194, 198
- General Electric 243
- genes 83
- genetic code 77
- genetics 77
- Genexol-PM 230
- Genia 127
- genomic medicine 197, 285, 334–335, 338, 344
- genomics 152
- genotype 95, 100, 103, 186, 246
- genotyping 100
- George M. Church 118
- Gerd Binnig 206
- German Cancer Research Center 337
- Gilead 198, 229, 233, 327
- Gilead Sciences 327
- Giving Pledge 342
- GlaxoSmithKline, Novartis, AstraZeneca, Merck, and Pfizer 321
- Gleevec *see* imatinib
- Global Alliance for Vaccines and Immunization 317
- glucagon 70, 214–215, 217, 281, 313
- glucose 39
- glutamic acid 58, 62
- glutamine 58, 61
- Glybera 276
- glycerol 41–43, 46
- glycine 58–59, 61
- glycoproteins 72, 93, 323, 326
- gold 24, 31–32, 143, 157
- Golgi 88, 93
- Gordon E. Moore 209
- GPCR *see* G protein-coupled receptors
- gross domestic product 359
- growth differentiation factor 11 258
- GSK 194, 198, 272
- guanine 46–48, 53, 78
- H *see* hydrogen
- H1N1 326
- H₂O 23–24, 38–39
- H5N1 *see* H1N1
- HAI *see* hospital-acquired infection
- Hansjorg Wyss 346
- haploid 84–85, 91
- HapMap Project 155
- Harvard Stem Cell Institute 258, 314, 355
- HCP *see* Human Connectome Project
- HDL 44
- HDSA *see* Huntington's Disease Society of America
- Health Level Seven International 340
- healthcare ecosystem 333
- healthcare expenses 360, 368–369
- heart transplants 261
- Heinrich Rohrer 206
- Helicos 121
- Heliscope 121
- Helmholtz Association 337
- hemagglutinin 326
- hemoglobin 70
- hepatitis B 178, 304, 323
- Herceptin 181, 185–187, 356
- heterozygous 95–96
- HGH *see* human growth hormone
- HGP *see* Human Genome Project
- HHMI *see* Howard Hughes Medical Institute
- hidden links 212–213
- high altitude 98
- high-throughput screening 168
- hippocampus 296–297

- Histidine 58–59
 HIV *see* human immunodeficiency virus
 HIV-AIDS 188
 HIV resistance 98
 HL7 *see* Health Level Seven International
 HMP *see* Human Microbiome Project
 homozygous 95–96
 hormones 292
 hospital-acquired infection 320
 Howard Hughes Medical Institute 272, 342
 HTS *see* high throughput screening
 Huanming Yang 147
 Human Brain Project 291
 human cloning 106
 Human Connectome Project 291
 human genome 81
 Human Genome Project 106
 human growth hormone 178, 270
 human immunodeficiency virus 98, 177, 188, 271, 315, 342
 human insulin 103, 178–179
 Human Microbiome Project 156, 288
 Humira 181, 356
 humoral immunity 316
 Huntington’s Disease Society of America 352
 Huntsman Cancer Institute 349
 hybridomas 180
 hydrogen 17–18
 hyperglycemia 312, 314
 hypoglycemia 217, 312
 hypoxia *see* oxygen starvation

 I *see* iodine
 IBM 128
 IBM, IBN *see* antimicrobial polymer nanoparticles
 IBM Research 129, 207, 212, 237

 IBM ZRL 206
 ibuprofen 169–170
 ICGC *see* International Cancer Genome Consortium
 IDEC 180–181
 IEEE 209
 IGR *see* Institut Gustave Roussy
 Illumina 116
 imatinib 185
 IMI *see* Innovative Medicines Initiative
 immune system 71, 97, 179–180, 185, 188, 223, 275, 282, 287, 309, 314, 316, 322–324, 332
 immunoglobulin 71–72, 308
 immunomodulators 266
 immunosuppressant drugs 261, 331
 immunotherapy 266
 impact 16, 373
 IND *see* Investigational Drug Application
 induced pluripotent stem 256, 258, 277
 infant mortality 359–362
 infectious diseases 315
 influenza 326
 influenza virus 326
 innovation 6
 Innovative Medicines Initiative 202
 Institut Gustave Roussy 338
 Institute of Oncology 338
 insulators 22, 37
 insulin 69
 intellectual property 7
 International Cancer Genome Consortium 307
 introns 81–82
 inversion 196
 investigational new drug (IND) application 173
 iodine 24, 32, 161
 ion channel 29, 160, 162

- ion-sensitive field-emission transistors 123
- Ion Torrent 123
- ionic 23
- ionization 36
- IP *see* cross-licensing
- ipilimumab 309
- IPO 11, 13–16, 374
- iPS *see* induced pluripotent stem
- iron 30
- iron oxide nanoparticles 231, 238
- ISFET *see* ion-sensitive field-emission transistors
- isoleucine 57–59

- Jackson Memorial Laboratory 343
- James Allison 309
- James Watson 77, 106, 143, 149
- Janssen 272, 278–279, 281
- JCR Pharmaceuticals 270
- JDRF *see* Juvenile Diabetes Research Foundation
- JEOL 243
- JHU *see* Johns Hopkins University
- Jian Wang 147, 149
- J&J 181, 198, 229, 250, 269
- J&J *see* Betalogsics
- J&J *see* Janssen
- Johns Hopkins University 4, 134, 257, 342, 354
- Jonathan Rothberg 115, 123, 125
- Juno Therapeutics 282
- JUSTICE 137
- Juvenile Diabetes Research Foundation 216, 352

- K *see* potassium
- Karolinska Institute 4–5, 338
- Kavli Institutes 347, 353
- Kavli Prizes 347
- KI *see* Karolinska Institute
- kidney transplants 261
- kinase 161, 186, 304
- Knight Cancer Institute at OHSU 350
- knockout mouse 165–166, 192
- KNOME 146
- Koch Institute 349

- lab-on-a-chip 246
- language 295
- language *see* speech
- Larry Ellison 346, 353
- LDL 44
- lead identification 167–168
- LED *see* light emitting diode
- left hemisphere 293, 295
- Leica 243
- Leroy Hood 111
- Leucine 58–60
- Li *see* lithium
- Life Sciences industry 201
- Life Technologies 119, 123, 134, 143–144
- ligase *see* ligation
- ligation 53, 104, 118–120
- light-emitting diode 245
- lipid 42
- Lipinski 169
- Lipitor 195
- Lipodox 227
- lipofection 224
- lipophilic 44, 172, 221
- liposomal nanodrugs 229
- liposomes 89, 223–228, 233–234
- lithium 28
- liver transplants 261
- lobes 34, 293–294
- LOC *see* lab-on-a-chip
- long-term potentiation 58, 297
- Lonza 270
- Louis Pasteur 33, 330
- LTP *see* long-term potentiation
- luciferase 115–116
- lupus 203, 309

- Luye 199
Lyme disease 315, 318
lysine 57–60
lysosome 88
- mab *see* monoclonal antibody
machine learning 212, 241
macular degeneration 182, 229, 270
magic bullets 179
magnesium 24, 29, 235
magnetic fluid hyperthermia 231
magnetic nanoparticles 231–232, 238
magnetic resonance force microscopy 237
magnetic resonance imaging 74, 235, 237, 295, 341
magnetoencephalography 241
malaria 98, 315, 342, 358–359
mammography 236
Marburg virus 323
Mario Capecchi, Martin Evans, and Oliver Smithies 258
Mateschitz *see* Red Bull
Max von Laue 68
Max-Planck Institutes 337
Mayo Clinic 146
McGovern Institute for Brain Research 347
MDR *see* multidrug resistant
measles 316–317, 329
Medarex *see* ipilimumab
Medical Research Council 109, 142, 337, 343
Medipost 272–273
MEG *see* magnetoencephalography
Meiji 243
meiosis 85–86, 91
membrane 86
membrane transport protein 164
Memorial Sloan Kettering Cancer Center 186, 282
memory 296
Mendel 83–85, 372
mesenchymal 254, 270, 272
mesoblast 270, 272
mesoderm 253–255
metabolic pathways 92, 287
metabolites 61, 89, 92, 154, 172, 288
metabolomics 154
metabonomics 154
metagenomics 154
metals 20, 22
metastasis 239, 246
methanogens 287
methicillin-resistant *S. aureus* 320
methionine 49, 57–58, 60
methylation 48–49, 110, 154–155
MFH *see* magnetic fluid hyperthermia
Mg *see* magnesium
MHLW *see* Ministry for Health, Labor and Welfare
micelle 220–222, 230
Michael Bloomberg 342
Michael J. Fox Foundation 348
Microbial Genome Project 156
microbiome 154, 156, 285–289, 314
microfluidics 116, 123, 130, 246–247
Mike Hunkapiller 111, 122
Mike Milken *see* Faster Cures
Milan *see* Institute of Oncology
minimally invasive surgery 302, 341
Ministry for Health, Labor and Welfare 340
MIS *see* minimally invasive surgery
MIT *see* Koch Institute
mitochondria 55, 89–90
mitochondrial genome 81
mitochondrion 55
mitosis 91, 251–252

- modeling and simulation 197,
 209–210, 373
 molecular cloning 103, 177–178
 molecules 17
 monoclonal antibody 308–309,
 356
 Moore's law *see* Gordon E. Moore
 morphogenesis 86, 91–92, 251
 morula 252–253
 MOSFET 209
 mosquito 315
 motor control 4, 293
 mountain sickness 98–99
 MPI *see* Max-Planck-Institutes
 MPI for neuroscience 337
 MRA *see* Myeloma Research
 Alliance
 MRC *see* Medical Research Council
 MRC *see* U.K. Medical Research
 Council
 MRFM *see* magnetic resonance
 force microscopy
 MRI *see* magnetic resonance
 imaging
 MRSA *see* methicillin-resistant
 Staphylococcus aureus
 MS *see* multiple sclerosis
 MSKCC *see* Memorial Sloan
 Kettering Cancer Center
 Mullis 100–101
 multidrug resistant 319
 multiple sclerosis 182, 272, 286,
 298
 multipotent 253, 255, 273
 muscle repair 259
 mutation 49, 96–98, 264, 266, 306
 Mycobacterium tuberculosis 317
 Myeloma Research Alliance 350
 Mylan 196, 198
 Myocet 227–229
 Myriad Genetics 141

 Na *see* sodium

 nano 1–2, 205, 225, 264
 nanochannel 123, 129–130
 nanocrystals 225–226, 233,
 244–245
 nanodiagnostics 243, 245, 247,
 249, 285
 nanomedicine 1, 3
 nanometer *see* nano
 nanoparticles 2, 217
 nanopore 124–130, 132, 145
 nanoscopy 242
 nanotoxicity 232
 Naproxen 169
 National Breast Cancer Coalition
 336
 National Cancer Center 338
 National Center for Biotechnology
 Information 152
 National Human Genome Research
 Institute 106, 306
 National Institutes of Health 106,
 166, 251, 288, 336, 372
 National Library of Medicine 152
 National Science Foundation 337
 NBCC *see* National Breast Cancer
 Coalition
 NCBI *see* National Center for
 Biotechnology Information
 NCC *see* National Cancer Center
 NCD *see* non-communicable
 diseases
 Neanderthal Man 143
 NeoStem 274–275
 neuraminidase 326–327
 neuraminidase inhibitors 327
 neurotransmitter 94, 162
 new molecular entity 167
 Nexium *see* Prilosec
 next-generation sequencing 113
 NGS *see* next generation
 sequencing
 NHGRI *see* National Human
 Genome Research Institute
 NHP *see* non-human primates

- NIDEK 264
NIFTY test 149
NIH *see* National Institutes of Health
NIH funding 342, 355–356
Nikon 243
nitrogen 26
NLM *see* National Library of Medicine
NME *see* new molecular ENTITY
NMR *see* nuclear magnetic resonance
Nobel *see* Nobel Prize
Nobel Prize 3
noncommunicable disease 357
nonhuman primates 142
nonsteroidal anti-inflammatory drugs 169
Novartis 194–195, 283
NSAID *see* nonsteroidal anti-inflammatory drugs
NSF *see* National Science Foundation
nuclear hormone receptors 163
nuclear magnetic resonance 35, 154, 236
nuclear medicine 31, 235, 240
nucleobases 46, 48, 78, 80
nucleosides 46, 50, 54, 78
nucleotides 50
Nuffield Council on Bioethics 142
- O *see* oxygen
Obamacare *see* Affordable Care Act
obesity 363
obsessive compulsive disorder 300
OCD *see* obsessive compulsive disorder
olfactory epithelium 290
oligopotent 253
Olympus 243, 280
omics 151–153, 155, 308
- oncogenes 305
ONPRC *see* Oregon National Primate Research Center
opposable thumb 292
orbitals 19–20, 22–23, 33–36
Oregon National Primate Research Center 105
Orencia 309
organogenesis 253
Organovo 271
orphan diseases 189, 196
oseltamivir 327
Osiris Therapeutics 272
ovum 85
Oxford Nanopore 124–127, 132
oxygen 27
oxygen starvation 297
- PacBio *see* Pacific Biosystems
Pacific Biosystems 121
paclitaxel 230, 232
palindromic 102
pancreas 214
pandemic 326, 328–329
Paracelsus 157–159, 348
parenteral 182, 229
Parkinson's disease 242, 298–299, 348
patents *see* intellectual property
pathogenic bacteria 317–319
Paul Ehrlich 179
Pauling 65
payers of health insurance 339
PCF *see* Prostate Cancer Foundation
PCR *see* polymerase chain reaction
PD *see* Michael J. Fox Foundation
PD *see* Parkinson's Disease
PD *see* pharmacodynamics
PDB *see* Protein Data Bank
PEG *see* polyethylene glycol
penicillin 318–320
peptide 63–66, 69–70, 162, 168

- peramivir 327
- periodic table 19–20, 22–24, 240
- personal genomics 118, 146
- personalized medicine 181, 183–185, 187–191
- PET *see* positron emission tomography
- Pfizer 194
- pharmacodynamics 172
- pharmacokinetics 172, 222, 233
- pharmacovigilance 176, 202
- phenotype 84, 95–96, 164–165, 254
- phenylalanine 57–59
- Philadelphia chromosome 186–187
- Philips 238, 243, 250
- phosphatases 161–162
- phosphodiester bond 51–52, 111
- phospholipids 44–45, 89, 94, 223–224, 323
- phosphorus 24, 26–27, 229, 235
- photolithography 119–120, 245
- pi-bonds 34
- piezoelectric 207–208
- pig kidneys 261
- Pixium Vision 264
- PK *see* pharmacokinetics
- placenta 252, 255, 270
- plague 98, 329
- pluripotent 253, 255–258, 273, 277
- Pluristem Therapeutics 274
- polio 179, 316–317, 330, 342, 344
- Polony sequencing 118
- polyethylene glycol 224
- polymer drugs 228
- polymerase chain reaction 100, 178
- polypeptide 64–67, 72, 88
- positron emission tomography 235, 307, 341
- potassium 24, 28–29, 32, 163, 235
- poverty line 363–366
- PPIs 184
- PPPs *see* public-private partnerships
- preclinical 160
- prenatal testing 139
- Prilosec 184, 187, 195
- prions 296
- Prograf *see* Tacrolimus
- prokaryote 86, 89, 287
- Proline 58, 60
- Prontosil 318
- proof of concept 129, 276
- Prostate Cancer Foundation 350
- proteases 161
- protein 63
- protein chip *see* protein microarray
- Protein Data Bank 69, 134
- protein microarray 246
- protein receptors 91, 93
- proteomics 149, 153, 193
- proton *see* hydrogen
- protoplasm 86
- providers 334
- Pseudomonas 317, 321
- public health 329
- public-private partnerships 166, 372
- purines 46–47, 51, 54, 61, 78
- pyrimidines 47–48, 51, 53–54, 61, 78
- pyrosequencing 114–117, 119, 123, 144, 154
- pyrrolisine 60
- QSAR *see* quantitative structure activity relations
- quantitative structure–activity relationships 169
- quantum 18
- quantum chemistry 19, 33, 36, 40, 168, 210
- quantum dot 244–245

- radiopharmaceutical 235
- radiotracers 235
- Ragon Institute 351
- Ranbaxy 199
- read length 124, 131–132
- recessive 83–84, 96, 265, 282
- recognition tunneling 130
- recombinant DNA 103, 177
- Red Bull 348
- regenerative medicine 251
- rejuvenation 258
- Remicade 181, 356
- Renagel 229–230
- renal transplantation 309
- Renvela *see* Renagel
- replication, transcription, and translation 82
- restriction enzymes 102–103
- retina 4–5, 182, 262–264, 290, 313
- Retina Implant AG 264
- retinal prostheses 263
- retinitis pigmentosa 263–264, 273
- retroviruses 327–328
- rheumatoid arthritis 181, 203, 277, 286, 290, 309
- rhodopsin 5, 161
- ribonuclease 71–72
- ribose 49–51
- ribosome 69, 82–83, 90, 318
- right hemisphere 293
- RIKEN 107, 113, 338
- Rituxan 180–181, 356
- RNA virus 323
- Robert Dennard 209
- Robert Koch 180, 330
- Roche 92, 116, 119, 122–124, 128–129, 132, 143–145, 169, 194, 198, 229, 233, 243, 250, 272
- Roche Diagnostics 123–124, 144
- rods 5, 262–263
- Roentgen 235
- Rosalind Franklin 77
- Rule-of-Five *see* Lipinski
- S *see* sulfur
- saccharides 39
- SALK Institute 344, 354
- Sangamo BioSciences 271
- Sanger 65, 82, 107, 109–115, 121, 131–132, 143, 154, 306, 343
- Sanger Centre 343
- Sanger sequencing 110–115, 131–132, 143, 154
- SANOFI 193–194
- SBH *see* sequencing-by-hybridization
- scanning probe microscopy 208
- scanning tunneling microscope 206, 208
- schizophrenia 142, 286, 291, 298, 347
- Schrödinger 18–19, 33, 35, 96, 245
- Schrödinger *see* quantum
- SCI *see* spinal cord injury
- SCID *see* severe combined immunodeficiency
- science philanthropy 354–355
- SCNT *see* somatic-cell nuclear transfer
- selenocysteine 56, 58, 62
- SEMATECH 199–200
- semiconductor industry 119, 199–201, 209, 245
- semiconductors 3, 22, 37, 199, 244
- sepsis 61, 159, 277, 320
- sequencing-by-hybridization 145
- Serine 58, 61
- serotonin 62, 161, 184–185
- severe combined immunodeficiency 257, 265
- Sherpas 100
- Shinya *see* Yamanaka
- Shire 196, 198, 271

- Shotgun sequencing 131
 Si *see* silicon
 sialic acid 326
 sickle-cell disease 62, 98
 Siemens 239, 243, 250
 sigma *see* orbitals
 sigma-bonds 34
 in silico 143, 168
 silicon 28
 silicon photonics 247
 SIMCERE 199
 single-molecule sequencing
 121–123
 single payer systems 362
 single-photon emission computed
 tomography 240
 smallpox 98, 316, 323, 329–330
 snip 100
 SNP *see* snip
 social computing 213
 societal impact 373
 sodium 29
 Solexa 116–117, 126, 143
 SOLiD 118–119, 143–144
 solubilization 221–222
 somatic cell nuclear transfer 104
 spatial navigation 297
 spatiotemporal reasoning 293
 SPECT *see* single-photon emission
 computed tomography
 speech 5, 292, 295, 300
 sperm 84–85
 spinal cord injury 271, 300
 SPM *see* scanning probe
 microscopy
 SSRIs 184
 St. Jude Children's Research
 Hospital 350
 Stanley Medical Research
 Institute 347
 Staphylococcus aureus 125, 318
 statins 188–189
 stealth liposomes 224
 stem cell 104, 251
 STEMCELL Technologies 279
 StemCells Inc 278
 steroid 43
 STM *see* scanning tunneling
 microscope
 strand sequencing 127
 stratified medicine 184, 188
 Streptococcus 317–318, 320
 Streptococcus pneumoniae 320
 structural proteins 163
 sulfur 22, 24, 28, 60, 235
 Sun Pharma 199, 227
 superbugs 319–320
 superresolution microscopy 242
 surfactant 220–221
 Susan G. Komen Foundation 351
 Svante Pääbo 143
 synapses 95, 162, 185, 242, 262,
 292
 Synthes 346

 T *see* thymine
 T1D *see* type 1 diabetes
 Tacrolimus 332
 Takeda 198, 204, 229, 233, 355
 Tamiflu *see* oseltamivir
 Taq polymerase 102
 target validation 164, 167
 Taxol *see* paclitaxel
 Tc *see* Technetium
 TCGA *see* The Cancer Genome Atlas
 Technetium 31, 240
 Teva 199, 233, 270, 272, 280, 283
 text analytics 211–213
 thalamus 294–296
 Thermo Fisher 119, 123, 144, 250
 threonine 57–58, 61–62, 73
 thymine 46–49, 53–54, 78, 80, 82,
 90
 Tibet 98
 TiGenix 277
 tissue engineering 260
 Toshiba 243, 250

- totipotent 253
- transcriptomics 149, 153
- transgenic animals 165
- translational medicine *see*
 - nanomedicine
- transplantation 330
- transplantation medicine 261, 331
- triglycerides 42–43, 46
- trophoblast 252
- tryptophan 57–58, 62, 184
- Tufts Center 191
- tumor suppressor genes 305
- tunneling 129–130, 206–208, 237
- Tylenol *see* acetaminophen
- type 1 diabetes 216, 290, 352
- tyrosine 58–59, 62–63, 186
- tyrothricin 318

- U *see* uracil
- uHTS 168, 193
- U.K. Medical Research Council 142
- ultrasound 235
- umbilical cord 255, 272–273, 280
- UMC *see* Uppsala Monitoring Centre
- unipotent 253
- UniQure 276
- Uppsala Monitoring Centre 176
- uracil 46–49, 53, 80, 82, 90
- US *see* ultrasound
- US Government Accountability Office 159
- Utah *see* Huntsman Cancer Institute

- vaccination 316–317, 341
- validated biomarkers 191
- valine 57–58, 62
- vancomycin-resistant
 - Enterococcus 320
- variant call format 134
- VCF *see* Variant Call Format

- VELVET 133–134
- venture capital 12, 14, 282–283, 373–374
- venture philanthropy 342
- vesicle 89, 92–95, 223
- vesicle traffic 92–93
- Viacyte 281, 314
- Vioxx 171
- viral envelope 323–324
- viral glycoproteins 323
- viral infections 229, 283, 304, 317, 322
- virus 322
- vision 5, 241, 262, 293
- visual perception 3, 5, 263–264
- in vitro 173
- Voyager Therapeutics 282
- VRE *see* vancomycin-resistant Enterococcus

- Wake Forest Institute for Regenerative Medicine 261
- Walter Gilbert 109
- Warren Buffett 342
- water *see* H₂O
- Watson–Jeopardy 212
- Wellcome Trust 107, 142, 306, 343, 353
- Wernicke’s (speech) area 295
- West Nile virus 323
- WFIRM *see* Wake Forest Institute for Regenerative Medicine
- WGS *see* whole genome sequencing
- Whitehead Institute 107, 345
- WHO *see* World Health Organization
- whole genome sequencing 132
- Wings for Life 303, 348
- World Health Organization 139, 176, 310, 327, 357
- Wyss Institute 346, 353

- X chromosome 85
- X-ray crystallography 68–70, 73, 77
- X-Rays *see* Roentgen

- Y chromosome 81, 85
- Yamanaka 256–258, 266, 281

- yeast cells 93, 179
- yellow fever virus 323
- Yervoy 309

- zanamivir 327
- Zeiss 242–243
- zinc finger nucleases 265
- zygote 85, 91, 251

